• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SA58鼻喷雾剂预防医护人员感染新型冠状病毒肺炎的安全性和有效性：一项开放标签、空白对照研究——中国内蒙古自治区呼和浩特市，2022年

Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.

作者信息

Si Shujie, Jin Canrui, Li Jianping, Cao Yunlong, Kan Biao, Xue Feng, Xie Xiaoliang Sunney, Fang Liang, Zeng Gang, Zhang Shuo, Hu Yaling, Dong Xiaoping

机构信息

Pharmacy Department, Inner Mongolia Fourth Hospital, Hohhot City, Inner Mongolia Autonomous Region, China.

Clinical Research and Development Department, Sinovac Biotech Co., Ltd., Beijing, China.

出版信息

China CDC Wkly. 2023 Mar 10;5(10):218-222. doi: 10.46234/ccdcw2023.040.

DOI:10.46234/ccdcw2023.040
PMID:37006441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10061814/
Abstract

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies.

WHAT IS ADDED BY THIS REPORT?: This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019 (COVID-19) infection in medical personnel for the first time.

WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: This study provides an effective approach for the public to reduce their risk of COVID-19 infection. The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.

摘要

关于该主题已知的信息有哪些？：SA58鼻喷雾剂的活性成分是一种广谱中和抗体，在体外研究中对不同的奥密克戎亚变体具有高中和能力。

本报告补充了哪些内容？：本研究首次证明了SA58鼻喷雾剂在医护人员中预防2019冠状病毒病（COVID-19）感染的安全性和有效性。

对公共卫生实践有何启示？：本研究为公众降低感染COVID-19的风险提供了一种有效方法。这项研究的结果有可能在COVID-19疫情爆发时显著降低感染风险并限制人际传播。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/cd0280fce640/ccdcw-5-10-218-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/43a6c9f426e1/ccdcw-5-10-218-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/26b3323ed167/ccdcw-5-10-218-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/cd0280fce640/ccdcw-5-10-218-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/43a6c9f426e1/ccdcw-5-10-218-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/26b3323ed167/ccdcw-5-10-218-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcc3/10061814/cd0280fce640/ccdcw-5-10-218-3.jpg

相似文献

1
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.SA58鼻喷雾剂预防医护人员感染新型冠状病毒肺炎的安全性和有效性：一项开放标签、空白对照研究——中国内蒙古自治区呼和浩特市，2022年
China CDC Wkly. 2023 Mar 10;5(10):218-222. doi: 10.46234/ccdcw2023.040.
2
Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Small-Scale Clinical Trial.鼻喷中和单克隆抗体 35B5 为预防严重急性呼吸综合征冠状病毒 2 变异株提供潜在保护：一项小规模临床试验。
Clin Infect Dis. 2023 Feb 8;76(3):e336-e341. doi: 10.1093/cid/ciac448.
3
Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial.海水加添加剂鼻喷雾剂对新冠病毒感染的早期阴性化作用：复兴开放标签对照临床试验
Pharmaceutics. 2022 Nov 18;14(11):2502. doi: 10.3390/pharmaceutics14112502.
4
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体，提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
5
The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.重组人干扰素 α 鼻用喷雾剂对疫区医务人员预防 COVID-19 肺炎的效果。
Curr Top Med Chem. 2021;21(10):920-927. doi: 10.2174/1568026621666210429083050.
6
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.从 SARS 康复者中合理鉴定有效的、广谱的沙贝科病毒中和抗体鸡尾酒。
Cell Rep. 2022 Dec 20;41(12):111845. doi: 10.1016/j.celrep.2022.111845. Epub 2022 Dec 1.
7
Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China.新型冠状病毒灭活疫苗对德尔塔变异株新型冠状病毒肺炎的有效性：来自中国内蒙古自治区一次疫情的证据
Vaccines (Basel). 2023 Jan 28;11(2):292. doi: 10.3390/vaccines11020292.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Human Plague Case Diagnosed in Ningxia Tracked to Animal Reservoirs - Inner Mongolia Autonomous Region, China, 2021.宁夏确诊的人类鼠疫病例追溯到动物宿主——中国内蒙古自治区，2021年
China CDC Wkly. 2021 Dec 24;3(52):1109-1112. doi: 10.46234/ccdcw2021.267.
10
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).靶向严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的广谱中和抗体 CT-P63 的临床前评估和随机 I 期研究。
Emerg Microbes Infect. 2022 Dec;11(1):2315-2325. doi: 10.1080/22221751.2022.2117094.

引用本文的文献

1
Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial.广谱抗SARS-CoV-2单克隆抗体SA55鼻喷雾剂在健康志愿者中的安全性和鼻腔滞留情况：一项I期临床试验
Pharmaceutics. 2024 Dec 31;17(1):43. doi: 10.3390/pharmaceutics17010043.
2
Real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19.鼻内喷雾 A8G6 抗体鸡尾酒在 COVID-19 暴露后预防中的真实世界效果。
Signal Transduct Target Ther. 2023 Oct 23;8(1):403. doi: 10.1038/s41392-023-01656-5.
3
Delivery of biologics: Topical administration.

本文引用的文献

1
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.从 SARS 康复者中合理鉴定有效的、广谱的沙贝科病毒中和抗体鸡尾酒。
Cell Rep. 2022 Dec 20;41(12):111845. doi: 10.1016/j.celrep.2022.111845. Epub 2022 Dec 1.
2
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.在完成初级接种程序和初始加强针接种后出现严重 COVID-19 结局：对英格兰、北爱尔兰、苏格兰和威尔士 3000 万人的全国前瞻性队列研究的汇总分析。
Lancet. 2022 Oct 15;400(10360):1305-1320. doi: 10.1016/S0140-6736(22)01656-7.
3
生物制剂的传递：局部给药。
Biomaterials. 2023 Nov;302:122312. doi: 10.1016/j.biomaterials.2023.122312. Epub 2023 Sep 4.
4
Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.SA58（抗 SARS-CoV-2 单克隆抗体）鼻喷剂用于健康成年工作人员预防有症状 COVID-19 的暴露后预防：一项随机、单盲、安慰剂对照的临床研究。
Emerg Microbes Infect. 2023 Dec;12(1):2212806. doi: 10.1080/22221751.2023.2212806.
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
BNT162b2 和科兴疫苗一剂、两剂和三剂对香港 COVID-19 的疫苗有效性：基于人群的观察性研究。
Lancet Infect Dis. 2022 Oct;22(10):1435-1443. doi: 10.1016/S1473-3099(22)00345-0. Epub 2022 Jul 15.
4
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
5
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎（B.1.1.529）和德尔塔（B.1.617.2）变异株的关系：一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
6
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.奥密克戎逃避了大多数现有的 SARS-CoV-2 中和抗体。
Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23.
7
Immunity to SARS-CoV-2 induced by infection or vaccination.由感染或接种疫苗引起的对 SARS-CoV-2 的免疫力。
J Intern Med. 2022 Jan;291(1):32-50. doi: 10.1111/joim.13372. Epub 2021 Aug 5.
8
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.结构解析的 SARS-CoV-2 抗体在严重感染的仓鼠中显示出高效力，并提供了一种有效的鸡尾酒配对策略。
Cell. 2020 Nov 12;183(4):1013-1023.e13. doi: 10.1016/j.cell.2020.09.035. Epub 2020 Sep 14.
9
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.高通量单细胞测序鉴定恢复期患者 B 细胞中的 SARS-CoV-2 强效中和抗体。
Cell. 2020 Jul 9;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. Epub 2020 May 18.